ethan basch , m.d. memorial sloan-kettering cancer center project overview may 24, 2010
DESCRIPTION
PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials. Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010 National Cancer Institute. Outline. Introductions Project background Progress to date - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/1.jpg)
PRO-CTCAE Face-To-Face Meeting #2Advancing the Science of Adverse Symptom
Monitoring in Cancer Treatment Trials
Ethan Basch, M.D.Memorial Sloan-Kettering Cancer Center
PROJECT OVERVIEW
May 24, 2010National Cancer Institute
![Page 2: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/2.jpg)
Outline1. Introductions2. Project background3. Progress to date4. Goals of the day
![Page 3: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/3.jpg)
Introductions
![Page 4: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/4.jpg)
Background“A PRO is any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else”
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdfz
![Page 5: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/5.jpg)
Background• PROs are standard in multiple
settings– Symptom efficacy evaluation in clinical
trials– HRQL– Patient satisfaction– Patient preferences
• But not standard for adverse symptom reporting
![Page 6: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/6.jpg)
Patient Experiences
Symptom
Clinician Interprets Symptom
Chart Representation
of Symptom
Data ManagerInterpretation of Symptom
ResearchDatabase
Current Model for Adverse Symptom Reporting in Cancer Trials
![Page 7: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/7.jpg)
Patient Experiences
Symptom
ResearchDatabase
Patient direct reporting of symptoms (1)
![Page 8: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/8.jpg)
Patient Experiences
Symptom
ResearchDatabase
Clinician
Patient direct reporting of symptoms (2)
![Page 9: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/9.jpg)
Patient Experiences
Symptom
ResearchDatabase
Clinician
Assign attribution; initiate expedited reporting
Patient direct reporting of symptoms (4)
![Page 10: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/10.jpg)
Patient Experiences
Symptom
ResearchDatabase
Clinician
Assign attribution; initiate expedited reporting
Enhance clinical care
Patient direct reporting of symptoms (5)
![Page 11: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/11.jpg)
Basch: NEJM, 2010Fromme: JCO, 2004Stromgren: Acta Anesth, 2001Weingart: Arch Intern Med, 2005Pakhomov: Am J Man Care, 2008Sprangers, Acta Oncologica, 2000
Clinicians systematically downgrade symptoms compared with patients
![Page 12: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/12.jpg)
Patient adverse symptom reports better correlate with functional status than clinician reports
Basch: JNCI, 2009
![Page 13: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/13.jpg)
Clinician CTCAE Reporting is Unreliable
• N=393 • Seen by 1st clinician in office, then 2nd clinician ~15
minutes later
Atkinson: SBM, 2010
![Page 14: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/14.jpg)
PROs Better Identify SAEs Early
• NCCTG 9741: Phase III trial comparing regimens for metastatic colorectal cancer
• Closed after 841/1,125 patients enrolled due to unexpected excess of early deaths in Arm 1 (“IFL”)– Associated with “GI syndrome” including severe
diarrhea
• Diarrhea reporting:– Clinicians reported CTCAE each cycle (diarrhea
required)– Patients reported diarrhea via in HRQL every other
cycleRothenberg: JCO, 2001
![Page 15: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/15.jpg)
Clinician-Reported Diarrhea
Dueck: Unpublished Data, 2010
![Page 16: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/16.jpg)
Patient-Reported Diarrhea
Dueck: Unpublished Data, 2010
![Page 17: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/17.jpg)
Patient vs. Clinician Diarrheain Arm 1 (IFL)
Dueck: Unpublished Data, 2010
![Page 18: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/18.jpg)
Development of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
• Initiated October 2008
NCI Contract HHSN261200800043C
![Page 19: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/19.jpg)
Mission
Develop a system for patient self-reporting of adverse symptoms in cancer trials which is widely accepted and used; generates useful data for investigators, regulators, clinicians and patients; and is compatible with existing adverse event reporting software systems
![Page 20: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/20.jpg)
PRO-CTCAE Network
NCI
ADVISORS TECH
NETWORK
NCCCP
MSKCCCoordinatin
gCenter
Dana-Farber
MD Anderson
Mayo
Duke
Penn
FDACooperative Groups
Industry
Christiana
Hartford
OLOL
Spartanburg
St. Joseph - Orange
SemanticBits
PerceptivePatientAdvocat
es
DCPDCCPS
DCTD
CBIIT
![Page 21: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/21.jpg)
Task-Based Project• Task 1: White paper and survey• Task 2: Item development• Task 3: Cultural literacy• Task 4: Cognitive interviews• Task 5: Technology development• Task 6: Usability testing• Task 7: Validation study• Task 8: Feasibility study• Task 9: Educational materials
Done O
ngoing
![Page 22: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/22.jpg)
Logistics
• Multidisciplinary committee for each task– NCI representatives– FDA representatives as appropriate– Patient advocates– Methodological expertise– Clinical expertise
• Regular web-enabled teleconferences– Digitally recorded– Documentation on Wiki
![Page 24: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/24.jpg)
PRO-CTCAE Presentations (2009-10)
• American Society of Clinical Oncology (ASCO)• International Society for Pharmacoeconomics
and Outcomes Research (ISPOR)• International Society for Quality of Life
Research (ISOQOL)• Drug Information Association (DIA)• caBIG Annual Meeting• Society of Clinical Trials (SCT)• Society of Behavioral Medicine (SBM)• Agency for Healthcare Research and Quality
(AHRQ)
![Page 25: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/25.jpg)
Goals of the Day
• Project update – Information exchange
• Discuss future directions and challenges1. Feasibility/implementation/dissemination2. Methodological/analytic issues
• Demonstrating does not generate noise3. Technology development
• Between-visit reporting• Integration with other systems
4. Regulatory issues
![Page 26: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/26.jpg)
Survey Highlights*729 Stakeholders in Cooperative Groups
QUESTION AGREE NEUTRAL DISAGREE
Systems to collect PROs in clinical trials should be developed
89% 5% 6%
In clinical trials, adverse events should be reported by patients
88% 8% 4%
POTENTIAL BARRIERS AGREE NEUTRAL DISAGREE
Lack of computers 69% 15% 16%
Limited personnel 57% 18% 25%
SOLUTIONS TO OVERCOME BARRIERS AGREE NEUTRAL DISAGREE
Funding (for personnel, dedicated space, training) 79% 13% 8%
Computers 72% 21% 7%
* Full survey results and White Paper available on project Wiki (https://wiki.nci.nih.gov/x/cKul)
![Page 27: Ethan Basch , M.D. Memorial Sloan-Kettering Cancer Center PROJECT OVERVIEW May 24, 2010](https://reader036.vdocuments.mx/reader036/viewer/2022081520/56816520550346895dd79f6a/html5/thumbnails/27.jpg)
Agenda